Immunity, HIV, Monoclonal Antibodies, and Ethical Considerations (Part 2/2) Revision Notes | A Level AQA Biology

1. Why Ethical Evaluation Matters in Immunology

Vaccines and monoclonal antibodies have transformed medicine — but the science alone does not settle every question. Who decides whether a vaccine should be compulsory? How do we weigh one person's risk against a whole population's benefit? These are not abstract philosophy questions; they appear directly in AQA exam questions under the command word evaluate.

This lesson builds on your knowledge of how vaccines and monoclonal antibodies work mechanistically. Here, the focus shifts to evidence quality and ethical reasoning — two skills that distinguish a grade-A response from a grade-C one.

2. Ethical Issues with Vaccines

Vaccination programmes sit at the intersection of individual rights and collective welfare. The central tension is this: a vaccine protects not only the person who receives it, but also those around them who cannot be vaccinated — newborns, immunocompromised individuals, and people for whom the vaccine is contraindicated.

This is the principle of herd immunity. When enough people in a population are immune, the pathogen cannot spread efficiently, so even unvaccinated individuals gain indirect protection. For measles, the herd immunity threshold is approximately 95% of the population — meaning if vaccination rates fall below this, outbreaks become likely.

The ethical debate therefore involves weighing autonomy (an individual's right to refuse a medical procedure) against beneficence (acting in the best interests of others) and non-maleficence (avoiding harm to the wider community). Neither side of this argument is scientifically wrong — they reflect genuinely competing values.

• Arguments for vaccination programmes: reduces disease burden, protects vulnerable individuals who cannot be vaccinated, can eradicate diseases (e.g. smallpox), cost-effective compared with treating disease
• Arguments against compulsory vaccination: infringes personal autonomy, religious or cultural objections, concerns about side effects (however rare), historical mistrust of medical institutions in some communities
• Middle-ground positions: incentivised rather than compulsory vaccination, transparent public communication about risk-benefit ratios, opt-out rather than opt-in systems

A recurring exam scenario involves a government considering making a vaccine compulsory. To evaluate this, you need to present both sides with evidence, then reach a reasoned conclusion — not list points on each side without judgement.

3. Ethical Issues with Monoclonal Antibodies

Monoclonal antibodies are produced using hybridoma technology, which involves fusing mouse B lymphocytes with tumour cells (myeloma cells). This raises distinct ethical concerns compared with vaccines, because the production process involves animal use and the treatments themselves are expensive and not universally accessible.

The use of animals in the production of monoclonal antibodies is regulated in the UK under the Animals (Scientific Procedures) Act 1986. Mice are immunised with the target antigen, their spleen cells are harvested, and hybridomas are created. Critics argue this causes animal suffering; proponents argue the medical benefits — including targeted cancer therapies — justify the procedure under the 3Rs framework (Replace, Reduce, Refine).

Access and cost present a second ethical dimension. Monoclonal antibody therapies such as trastuzumab (Herceptin) for HER2-positive breast cancer can cost tens of thousands of pounds per patient per year. Decisions about which treatments the NHS funds involve rationing — a process managed by NICE (National Institute for Health and Care Excellence) using cost-effectiveness analysis. This raises questions about equity: should a treatment be withheld from patients solely on grounds of cost?

A third concern relates to side effects. Because monoclonal antibodies bind with high specificity to their target antigen, off-target effects are generally lower than with conventional chemotherapy. However, they are not zero — some patients experience immune reactions, including cytokine release syndrome, which can be severe. Informed consent requires that patients understand these risks before treatment begins.

4. Evaluating Methodology and Evidence

AQA expects you to do more than recall ethical arguments — you must also evaluate the quality of evidence used to support claims about vaccines and monoclonal antibodies. This means understanding what makes a clinical trial reliable and valid, and being able to identify weaknesses in published data.

The gold standard for evaluating a new vaccine or therapy is the randomised double-blind placebo-controlled trial. Participants are randomly assigned to either the treatment group or the placebo group. Neither the participants nor the researchers administering the treatment know who received which — this is the double-blind element. Randomisation controls for confounding variables; blinding controls for placebo effect and observer bias.

When you encounter data in an exam question — for example, a graph showing vaccine efficacy over time, or a table comparing adverse event rates — your job is to interrogate it. Ask: how large was the sample? Was there a control group? Were the groups matched for age and health status? Was the study peer-reviewed? These questions form the backbone of a high-quality evaluate response.

5. Interpreting Data on Vaccine Safety and Efficacy

One of the most important skills in this topic is distinguishing between correlation and causation. A famous historical example is the now-retracted 1998 Wakefield study, which claimed a link between the MMR vaccine and autism. The study used only 12 children, had no control group, and was later found to involve data manipulation. Despite being retracted, the study caused lasting damage to public confidence in vaccination — demonstrating how flawed methodology can have real-world consequences.

In contrast, large-scale epidemiological studies involving millions of children across multiple countries have consistently found no association between MMR vaccination and autism. The weight of evidence — from studies with large samples, appropriate controls, and independent replication — supports the safety of the MMR vaccine. This is the kind of evidence evaluation AQA expects you to perform.

The trend above illustrates the population-level impact of the MMR programme introduced in 1988. When evaluating such data, note that correlation between vaccine introduction and disease decline is supported by the biological mechanism (vaccine-induced immunity reduces transmission), strengthening the causal inference. However, you should also consider confounding factors such as improved sanitation or changes in reporting practices.

6. Comparing Arguments: A Structured Approach

When an exam question asks you to evaluate the use of vaccines or monoclonal antibodies, a common mistake is to list points without reaching a conclusion. The examiner is looking for a reasoned judgement that weighs the evidence on both sides.

A reliable structure for a 6-mark evaluate response is: state your overall position clearly, present the strongest evidence in favour, present the strongest evidence against (or a limitation), address a counter-argument, and then reaffirm your conclusion with reference to the balance of evidence. This mirrors the structure used in scientific review articles.

Worked example: Structuring a 6-Mark Evaluate Response

Evaluate the use of monoclonal antibodies in the treatment of cancer. [6 marks]

1. Monoclonal antibodies represent a significant advance in cancer treatment, offering targeted therapy with fewer off-target effects than conventional chemotherapy. — Open with a clear, direct judgement. Do not hedge at the start — the examiner needs to see you can reach a conclusion. [B1]
2. Monoclonal antibodies such as trastuzumab bind specifically to HER2 receptors overexpressed on certain breast cancer cells, triggering immune destruction of the tumour while leaving normal cells largely unaffected. Clinical trial data show improved survival rates compared with chemotherapy alone in HER2-positive patients. — Link the mechanism to the clinical outcome. Specific named examples earn marks. [B1 for mechanism, B1 for clinical evidence]
3. However, monoclonal antibody therapies are expensive — often exceeding NICE cost-effectiveness thresholds — meaning access is not universal. Additionally, some patients experience immune reactions including cytokine release syndrome, and therapies are only effective for patients whose tumours express the target antigen. — A genuine limitation, not a straightforward one. Cost, access, and patient selection are all scientifically and ethically relevant. [B1 for limitation]
4. The concern about cost must be weighed against the long-term savings from avoiding prolonged chemotherapy and hospitalisation, and the ethical imperative to offer effective treatments where they exist. — Showing you can argue against your own limitation demonstrates higher-order thinking. [B1]
5. On balance, the evidence supports the use of monoclonal antibodies in cancer treatment where the target antigen is confirmed and the therapy is cost-effective. Continued investment in reducing production costs and expanding access would strengthen the case further. — The conclusion must be justified by the evidence presented, not restated. [B1 for reasoned conclusion]

Answer: A full 6-mark response presents a clear position, specific mechanistic and clinical evidence, a genuine limitation, a counter-argument, and a justified conclusion — not a list of bullet points.

7. Exam Technique and Common Mistakes

The most common error in evaluate questions on this topic is treating the question as a describe question — listing facts about how vaccines or monoclonal antibodies work, without engaging with the ethical or evidential dimension. The command word evaluate requires you to weigh evidence and reach a conclusion; marks are explicitly awarded for judgement, not just recall.

A second frequent error is making unsupported assertions about safety. Statements such as "vaccines are completely safe" or "monoclonal antibodies have no side effects" will not earn marks and may actively lose them if they contradict the data provided in the question. Always qualify claims: "the evidence from large-scale trials suggests the benefits outweigh the risks for the majority of patients."

When a question provides data — a graph, table, or percentage — always refer to it explicitly in your answer. Examiners award marks for using the data, not for general statements that could have been written without reading the question. Quote figures, describe trends, and link them to the biological mechanism.

Across this lesson, the core skill has been the same: use scientific evidence to reach a reasoned, qualified judgement. Whether the question is about vaccine ethics, monoclonal antibody access, or trial methodology, the examiner is testing your ability to think like a scientist — not just recall facts, but weigh them.